Autopsy report · NCT02974322
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Cause of deathFunding or business
“Sponsor decision not to start trial”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 3
- Sponsor
- Celgene
- Sponsor type
- Industry
- Conditions
- Crohn Disease
- Interventions
- GED-0301; Placebo
- Participants
- 0
- Sites
- 311
- Countries
- Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary and more
Trials that died the same way
- CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
“Sponsor decision to not initiate the trial” - A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
“The sponsor decided not to conduct the expansion part of trial (part 2)” - A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
“Sponsor decision to cancel trial, not related to safety concern.” - A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer
“Decision was made by Sponsor to stop the trial.” - A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
“Trial was cancelled by Sponsor”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.